Targeted ligand modification decorates nanodrug surfaces with specific ligands that bind to receptors overexpressed on tumor cells, such as transferrin receptor (TfR), folate receptor (FR), and epidermal growth factor receptor (EGFR) (Dhar et al., 2022). The gene discussed is EGFR; the disease is neoplasm.